DAVITA INC.
boothcheck covers DAVITA INC. (DVA) but does not put one priced-in number on it: here the defensible answer is the evidence rather than a point estimate. boothcheck publishes no house fair value, target price, or buy/sell rating. Narrative composed July 26, 2026.
• Roughly two-thirds of the revenue line comes from government programs and about 31% from commercial insurance, and the commercial third is where the profit is concentrated. • Treatments are not growing: the company performed 28.73 million dialysis treatments in 2025 against 29.05 million in 2024, and revenue rose only because the rate per treatment did, from 391.32 dollars to 409.56 dollars. • Share count is doing the work instead: weighted average basic shares fell to 67.4 million in the firs
Is DVA overvalued? See what's priced in →
565 institutional managers reported holding DVA in 13F filings for the quarter ended 2026-03-31. Together they hold about 90% of the company; the top 10 hold 66%. 119 opened new positions that quarter. Held by Berkshire Hathaway, Vanguard Group, BlackRock, among others. On the short side, 4.6M shares were sold short as of the 2026-06-15 count, about 7% of shares outstanding (6 days of typical volume to cover).
Quarterly 13F filings arrive up to 45 days after quarter end, so the picture is never current (filed through 2026-05-29). Nothing here is investment advice.
DVA has cut its share count 36.6% over the past five years, spending $5.64B on repurchases. It pays no dividend. Cash returned over the past three years: $3.85B in repurchases.
Share counts are split-adjusted; repurchase totals are gross of share issuance. Nothing here is investment advice.
No open-market insider buys on file at DVA over the trailing three years. Absence is a fact about the company, not a signal. 16 officers and directors are on file.
Code P open-market purchases from SEC Form 4 filings, non-derivative, excluding scheduled 10b5-1 plans. Nothing here is investment advice.
DVA's recent reports: the day-one move, then what the following quarter actually did.
| report | day one | next quarter |
|---|---|---|
| 2023-08-04 | +6.7% | -17.7% |
| 2023-11-08 | +7.4% | +29.3% |
| 2024-02-15 | +8.0% | +5.2% |
| 2024-05-03 | -3.8% | +1.5% |
Day-one is the close-to-close move around the filing. Nothing here is investment advice.
DVA's latest 8-K filings: 2026-08-04 (items 2.02, 9.01); 2026-06-08 (items 1.01, 2.03, 5.07, 9.01); 2026-05-05 (items 2.02, 9.01); 2026-02-02 (items 2.02, 9.01); 2025-11-25 (items 1.01, 2.03, 9.01).
Item codes are the SEC's own classification of what each report discloses. Dates link to the filing on EDGAR. Nothing here is investment advice.
Model solve date: 2026-Q2
Narrative composed: July 26, 2026
Each week boothcheck ranks the stocks whose prices are betting on the most. Read the most stretched bets archive →
boothcheck is also on Android. Get the app on Google Play →
For informational and research purposes only. Not investment advice. Not a recommendation to buy, sell, or hold any security. boothcheck is not a registered investment adviser. Past performance does not guarantee future results.